Skip to content

Author

C. Sanchez

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Standard versus extended dual antiplatelet therapy after pci in acute coronary syndrome: a systematic review and meta-analysis

The absence of benefit was confirmed both during overall follow-up and in landmark 12-month analyses, with a reduction observed only in repeat revascularisation, a softer endpoint, and findings support an individualised approach to DAPT duration rather than routine prolongation beyond one year.

A. Gasca, N. Murillo, S. Cordoba et al. · 0 citations
Open access Oct 2026

The LIRA-HF trial: liraglutide in heart failure with reduced ejection fraction and obesity – a 30-month randomized trial

GLP-1 receptor agonists reduce cardiovascular events in type 2 diabetes, but their role in heart failure with reduced ejection fraction (HFrEF) remains controversial due to concerns over heart rate elevation and potential arrhythmogenicity observed in prior trials. To evaluate whether liraglutide added to...

R. R. Sabido, M. Lagunas, Y. Jiménez et al. · 0 citations
Open access Oct 2026

The ACETAZ-HF trial: intravenous furosemide plus oral acetazolamide for rapid decongestion in acute HFrEF and sustained outpatient benefit

Rapid and sustained decongestion in acute heart failure with reduced ejection fraction (HFrEF) remains a therapeutic challenge, particularly in patients with diuretic resistance. Sequential nephron blockade with acetazolamide may enhance decongestion during hospitalization and, when continued intermittently after...

R. Sabido, S. Ramos, M. Lagunas et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.